Discordance of Somatic Mutations Between Asian and Caucasian Patient Populations with Gastric Cancer

Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

(2014) Jacques Ferlay et al.   INTERNATIONAL JOURNAL OF CANCER

Lapatinib Plus Paclitaxel Versus Paclitaxel Alone in the Second-Line Treatment ofHER2-Amplified Advanced Gastric Cancer in Asian Populations: TyTAN—A Randomized, Phase III Study

(2014) Taroh Satoh et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study

(2014) Takashi Seto et al.   LANCET ONCOLOGY

Comprehensive molecular characterization of gastric adenocarcinoma

(2014) Adam J. Bass et al.   NATURE

Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma

(2014) Miwako Kakiuchi et al.   NATURE GENETICS

Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer

(2014) Kai Wang et al.   NATURE GENETICS

Identification of Molecular Subtypes of Gastric Cancer With Different Responses to PI3-Kinase Inhibitors and 5-Fluorouracil

(2013) Zhengdeng Lei et al.   GASTROENTEROLOGY

Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study

(2013) Atsushi Ohtsu et al.   JOURNAL OF CLINICAL ONCOLOGY

Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial

(2013) Tom Waddell et al.   LANCET ONCOLOGY

Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial

(2013) Florian Lordick et al.   LANCET ONCOLOGY

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

(2012) Li Zhang et al.   LANCET ONCOLOGY

Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes

(2012) Zhi Jiang Zang et al.   NATURE GENETICS

Implementing Personalized Medicine in a Cancer Center

(2011) David A. Fenstermacher et al.   CANCER JOURNAL

Gene Expression Signature-Based Prognostic Risk Score in Gastric Cancer

(2011) J. Y. Cho et al.   CLINICAL CANCER RESEARCH

A framework for variation discovery and genotyping using next-generation DNA sequencing data

(2011) Mark A DePristo et al.   NATURE GENETICS

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

(2010) Federica Di Nicolantonio et al.   JOURNAL OF CLINICAL INVESTIGATION

ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data

(2010) K. Wang et al.   NUCLEIC ACIDS RESEARCH

Fast and accurate short read alignment with Burrows-Wheeler transform

(2009) H. Li et al.   BIOINFORMATICS

Non-steroidal anti-inflammatory drugs and risk of gastric and oesophageal adenocarcinomas: results from a cohort study and a meta-analysis

(2009) C C Abnet et al.   BRITISH JOURNAL OF CANCER

Dietary glycemic load and gastric cancer risk in Italy

(2009) P Bertuccio et al.   BRITISH JOURNAL OF CANCER

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Emerging ethnic differences in lung cancer therapy

(2008) I Sekine et al.   BRITISH JOURNAL OF CANCER

On the Eve of Personalized Medicine in Oncology

(2008) T. J. Yeatman et al.   CANCER RESEARCH